Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,561.67 -32.96 (-0.72%) Dow
36,168.66 -76.84 (-0.21%) Nasdaq
14,145.03 -160.00 (-1.12%) Bitcoin USD
41,722.13 +2,154.90 (+5.45%) CMC Crypto 200
858.05 -0.66 (-0.08%)
Spruce Biosciences, Inc. (SPRB)
| Previous close | 1.4900 |
| Open | 1.5200 |
| Bid | 1.5500 x 1000 |
| Ask | 1.5700 x 900 |
| Day's range | 1.4850 - 1.5800 |
| 52-week range | 0.9550 - 3.5700 |
| Volume | |
| Avg. volume | 117,712 |
| Market cap | 63.33M |
| Beta (5Y monthly) | 2.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings date | 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.33 |
Business WireSpruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., November 13, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
Business WireSpruce Biosciences to Participate in the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., November 02, 2023--Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
Business WireSpruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
SOUTH SAN FRANCISCO, Calif., October 18, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipat
